Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib ± Apatinib for Ovarian Cancer
ChiCTR2200059011Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Feb 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluzoparib and Rivoceranib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200059011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059011.